HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Apple, F. S. Articles by Murakami, M. M. Search for Related Content PubMed PubMed Citation Articles by Apple, F. S. Articles by Murakami, M. M. Related Collections Proteomics and Protein Markers

Point-of-Care i-STAT Cardiac Troponin I for Assessment of Patients with Symptoms Suggestive of Acute Coronary Syndrome,

Hennepin County Medical Center and University of Minnesota School of Medicine, Department of Laboratory Medicine and Pathology, Minneapolis, MN;

^aaddress correspondence to this author at: Hennepin County Medical Center, Clinical Laboratories MC P4, 701 Park Ave., Minneapolis, MN 55415; fax 612-904-4229, e-mail fred.apple{at}co.hennepin.mn.us)

Abstract

Background: Few studies have investigated the role of cardiac troponin point-of-care (POC) testing for predicting adverse outcomes in acute coronary syndrome (ACS) patients. We investigated the use of a POC cTnI assay in ACS patients.

Methods: We studied consecutive patients (n = 367) presenting with symptoms suggestive of ACS who were admitted through the emergency department. We measured plasma cTnI with the i-STAT assay. Patients were risk-stratified based on cTnI concentrations defined by the predetermined 99th percentile reference limit for plasma (0.04 µg/L). Patients were followed for 60 days. We computed survival and event curves with the Kaplan–Meier method and compared risk stratification groups with the log-rank test.

Results: Acute myocardial infarction (MI) was diagnosed in 8.1% of patients. Odds ratios and 95% confidence intervals for all-cause death (ACD), MI or ACD, MI or cardiac death, and cardiac death at 60 days were all statistically significant after adjustment for age, diabetes, hypertension, and history of renal failure as follows: 2.54 (1.24–5.20), P = 0.009; 2.76 (1.37–5.58), P = 0.003; 5.98 (1.65–21.7), P = 0.008; and 2.54 (1.24–5.20), P = 0.009. Kaplan–Meier curves showed early separation between patients with increased vs. reference concentrations before 30 days for ACD, MI or ACD, and MI or cardiac death.

Conclusion: The i-STAT POC cTnI assay can be added to the list of assays for risk stratification.

The following articles in journals at HighWire Press have cited this article:

				P. N. Floriano, N. Christodoulides, C. S. Miller, J. L. Ebersole, J. Spertus, B. G. Rose, D. F. Kinane, M. J. Novak, S. Steinhubl, S. Acosta, et al. Use of Saliva-Based Nano-Biochip Tests for Acute Myocardial Infarction at the Point of Care: A Feasibility Study Clin. Chem., August 1, 2009; 55(8): 1530 - 1538. [Abstract] [Full Text] [PDF]

				A. A. Fisher, E. K. Southcott, W. Srikusalanukul, M. W. Davis, P. E. Hickman, J. M. Potter, and P. N. Smith Relationships between Myocardial Injury, All-cause Mortality, Vitamin D, PTH, and Biochemical Bone Turnover Markers in Older Patients with Hip Fractures Ann. Clin. Lab. Sci., January 1, 2007; 37(3): 222 - 232. [Abstract] [Full Text] [PDF]